NAT14

Across TCGA pan-cancer cohorts, NAT14 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NAT14 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NAT14 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NAT14 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, GBM, and UCEC are the cancer types where NAT14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.280	0.462	.002	13	view →
GBM	OS	Quartile	All	0.667	0.431	.024	4	view →
UCEC	DFS	Median	All	0.783	0.930	.020	4	view →
LUAD	DFS	Median	II,III,IV	0.907	0.792	.034	2	view →
CCRCC	OS	Median	All	0.809	0.925	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NAT14–PDAC (DFS)

Open the PDAC breakdown →